MaaT Pharma (MAAT) 2.86 EUR (-0.17%) | Healthcare & Biotech Euronext / Paris

MaaT Pharma is a biopharmaceutical company specializing in the development of microbial therapies for the treatment of serious diseases.

Comment

Performance & Momentum

6 Months 29.33 %

1 Year 44.94 %

3 Years 60.80 %

5 Years 97.98 %

Momentum

Unlock this indicator

Recent News

MaaT Pharma

MaaT Pharma Reports Promising Clinical and Q3 Results

7 months ago

MaaT Pharma announced significant progress, including positive Phase 3 results for Xervyteg® in acute graft-versus-host disease presented at the ASH 2025 conference. The company also released updated preclinical data showing immune activation and promising antitumor activity for its candidate MaaT034. Additionally, MaaT Pharma published its Q3 2025 financial results along with a financing update. These developments boost confidence in the company’s clinical pipeline and could support medium-term investor interest.

source: anantys.com • biotech, pharmaceutical

Strategic Analysis

MaaT Pharma is positioned in a highly specialized niche of medical biotechnology, with microbial therapies intended to treat severe diseases. Its business model relies on a differentiated scientific approach, but remains dependent on clinical success, regulatory approval, and funding for its development.

Strengths

Niche positioning in microbial therapies, with strong scientific differentiation
Exposure to a healthcare segment with significant unmet medical need, potentially attractive if clinical results are validated
French roots and a pure innovation profile, likely to draw interest around targeted medical advances

Weaknesses

High dependence on clinical trial outcomes and regulatory milestones
Still limited commercial visibility, typical of a biotechnology company in the development phase
Deteriorated stock momentum, reflecting weak market confidence and higher financing risk

Momentum

Momentum appears clearly weak and the market trend remains unfavorable, with persistent pressure on the stock across multiple time horizons. Strategically, this suggests that the share remains primarily a speculative story, where upside depends on scientific or regulatory catalysts rather than on an established stock-market uptrend.

Analysis performed 1 week ago